- Home
- PSHG vs CTXR Comparison
PSHG vs CTXR Comparison
Compare PSHG & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | CTXR |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 18.7M |
| IPO Year | 2010 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PSHG | CTXR |
|---|---|---|
| Price | $1.69 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 36.4K | ★ 982.8K |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | $147.57 |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.47 |
| 52 Week High | $2.58 | $2.19 |
Technical Indicators
Market Signals| Indicator | PSHG | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 50.44 |
| Support Level | $1.61 | $0.51 |
| Resistance Level | $1.89 | $0.76 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.32 | 29.57 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a shipping company. The company is a provider of shipping transportation services through the ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying container vessels and cargo along various shipping routes. It owns and operates Aframax and Suezmax tanker vessels.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.